ACM
IDYA icon

ACT Capital Management’s IDEAYA Biosciences IDYA Stock Holding History

ACT Capital Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-173,500
Closed -$2.39M – 76
2022
Q2 		$2.39M Hold
173,500
– – 3.35% 10
2022
Q1 		$1.94M Hold
173,500
– – 2.05% 12
2021
Q4 		$4.1M Hold
173,500
– – 2.97% 7
2021
Q3 		$4.42M Buy
173,500
+104,300
+151% +$2.44M 2.29% 9
2021
Q2 		$1.45M Buy
+69,200
New +$1.42M 0.75% 31

Other funds holding IDYA

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACT Capital Management's IDYA Position: Q3 2022 in Review

ACT Capital Management sold out of IDEAYA Biosciences (IDYA) in Q3 2022, closing a stake of 173,500 shares — an estimated $2.39M sold.

ACT Capital Management first reported a position in IDYA in Q2 2021 and held it in 5 quarters. The position peaked at $4.42M in Q3 2021. 112 funds tracked by Wall St. Rank hold IDYA as of Q3 2022.

  • ACT Capital Management reported no remaining IDEAYA Biosciences position as of Q3 2022 after selling out during the quarter.
  • ACT Capital Management sold 173,500 IDEAYA Biosciences shares in Q3 2022, an estimated $2.39M.
  • ACT Capital Management first reported a position in IDEAYA Biosciences in Q2 2021 and held it in 5 quarters.
  • ACT Capital Management's IDEAYA Biosciences position peaked at $4.42M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.